Altium Capital founder Jacob Gottlieb is in the market for healthcare and medical treatment investments. Based in New York City, Gottlieb holds a medical degree from NYU Medical School and brings real healthcare knowledge to the investment environment. Gottlieb has partnered with Stuart Weisbrod, of Merlin BioMed Group, a proven investor with positions in Oracle Partners, Harpel Partners, Merrill Lynch, and Prudential-Bache Securities. At its height, Merlin achieved an investor 100% return rate for clients such as major pension funds, endowments, and high-value investors.
The investment strategy behind Altium is similar to Merlin. The focus remains on public healthcare companies that include:
Altium Capital Progress
Altium has already provided a position for Oramed Pharmaceuticals (ORMP). ORMP has been successful in developing an oral diabetic treatment, in the form of an insulin capsule, to replace injectable diabetic treatment. And, latest venture: Altium is currently researching and providing a position with SELLAS Life Sciences Group. SELLAS is a biopharmaceutical company focused on developing cancer immunotherapy treatment across multiple cancer types.
Good partnerships not only create treatment-based medical initiatives, but remain good philanthropic business. Gottlieb takes Altium Capital into the philanthropic arena with charitable contributions to Math for America, the Robin Hood Foundation, and Covenant House. Math for America focuses on the recruitment/retention of NYC mathematics teachers at the secondary school level. The Robin Hood Foundation provides NYC nonprofit organizations with financial, real estate and management aid. Covenant House is a national, privately-funding organization providing shelter and services to displaced and/or homeless young people within NYC and the nation.
As Altium Capital targets healthcare with an eye to philanthropy and investment, stakeholder partnerships continue viability for mutual benefit.